{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:33:14Z","timestamp":1793093594361,"version":"4.5.0"},"reference-count":37,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR213331"],"award-info":[{"award-number":["NIHR213331"]}],"id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the value of serum type I interferon (IFN) score in predicting clinically meaningful progression in limited cutaneous systemic sclerosis (lcSSc) using a novel composite endpoint adopted from the MINIMISE clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, longitudinal lcSSc cohort was identified within a national, multicenter observational cohort. The MINIMISE trial combined Morbi\u2010mortality endpoint was used as the clinical outcome for a time to clinical worsening (TTCW) design. The IFN score was calculated from the serum concentration of chemokine C\u2010C motif ligand (CCL) 2, CCL8, CCL19, C\u2010X\u2010C motif chemokine ligand (CXCL) 9, CXCL10, and CXCL11 on patients and age\u2010 and sex\u2010matched healthy controls (HCs). A \u201chigh\u201d IFN score was defined as 2 SDs above the HC mean. The association of the IFN score with TTCW was assessed using Cox proportional hazard regressions and Kaplan\u2010Meier curves. The potential improvement in risk stratification when combining IFN score with lcSSc clinical features was explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 149 patients were included in the analysis: 67 \u201chigh\u201d IFN and 82 \u201clow.\u201d High IFN patients presented a shorter TTCW (74.7 months [95% confidence interval (CI) 70.1\u201379.3] vs 110.6 months [95% CI 107.2\u2013114.0];\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) and met the endpoint in higher proportion compared with low IFN (55% vs 12%;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). A high IFN score conferred hazard ratio (HR) 5.5 (95% CI 2.7\u201311.3) for TTCW compared with low IFN, and IFN score as a continuous variable conferred HR 2.38 (95% CI 1.4\u20134.0) for TTCW independently of clinical variables. Pulmonary arterial hypertension, interstitial lung disease, digital ulcers, and modified Rodnan skin score were associated with TTCW. An exploratory analysis showed that these clinical features improve risk stratification over time in combination with IFN score.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum assessment of type I IFN activity is a valuable predictor of clinically meaningful outcomes in lcSSc. The combination of serum IFN score with sentinel clinical features can improve stratification strategies in clinical trials and patient management.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/art43120-toc-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.43120","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T01:00:28Z","timestamp":1738198828000},"page":"929-941","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis"],"prefix":"10.1002","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1256-0761","authenticated-orcid":false,"given":"Stefano","family":"Di Donato","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Biomedical Research Centre, National Institute for Health Research, Leeds Teaching Hospitals NHS Trust  Leeds United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7750-4280","authenticated-orcid":false,"given":"Rebecca","family":"Ross","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds  Leeds United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjitha","family":"Karanth","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds  Leeds United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Biomedical Research Centre, National Institute for Health Research, Leeds Teaching Hospitals NHS Trust  Leeds United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9819-105X","authenticated-orcid":false,"given":"Enrico","family":"De Lorenzis","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley\u2010Anne","family":"Bissell","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Biomedical Research Centre, National Institute for Health Research, Leeds Teaching Hospitals NHS Trust  Leeds United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Clark","sequence":"additional","affiliation":[{"name":"University College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Yee","sequence":"additional","affiliation":[{"name":"University College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[{"name":"University College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-2283","authenticated-orcid":false,"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Biomedical Research Centre, National Institute for Health Research, Leeds Teaching Hospitals NHS Trust  Leeds United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/2397198320961967"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102452"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02672-y"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38029"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044765"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41153"},{"key":"e_1_2_6_9_1","unstructured":"Mycophenolate in limited cutaneous systemic sclerosis (MINIMISE\u2010Pilot).ClinicalTrials.govidentifier NCT04927390.2023. Accessed July 27 2023.https:\/\/clinicaltrials.gov\/study\/NCT04927390"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcp174"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000907"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502190"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20160"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218439"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00004711"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.595811"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42662"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.302221"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030491"},{"key":"e_1_2_6_20_1","article-title":"Serum interferon score is a biomarker of active disease in patients with early diffuse cutaneous systemic sclerosis enrolled in the prospective registry of early systemic sclerosis (PRESS) cohort","author":"Hinchcliff M","journal-title":"Lancet Rheum"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424"},{"issue":"2","key":"e_1_2_6_22_1","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy EC","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00337.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2005.030814.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41627"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207392"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215145"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02026-2019"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205897"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez558"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04564-8"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215787"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1740-2557-6-2"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2021.1887927"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03141-4"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090815"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30007-2"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101648"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.43120","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:11:42Z","timestamp":1773025902000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.43120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/art.43120"],"URL":"https:\/\/doi.org\/10.1002\/art.43120","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"2024-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}